Home

arrow iconNewsarrow iconarrow icon

FERSOG - Ghana Must Recognize Infertility as Disease

FERSOG - Ghana Must Recognize Infertility as Disease

The Fertility Society of Ghana has urged the government to officially recognize infertility as a disease and include basic fertility services in the National Health Insurance Scheme during its eighth Annual General meeting, held in Tema.

By FertilityIn

08 May 2026

3 min read

The Fertility Society of Ghana

The Fertility Society of Ghana

The Fertility Society of Ghana (FERSOG) has intensified calls for the government to officially recognize infertility as a disease, aligning with international health standards set by the World Health Organization (WHO). The society made this appeal during its eighth Annual General Meeting and Scientific Conference, which took place on October 16-18, 2025.



Dr. Rudolph Kantum Adageba, President of FERSOG, described the current healthcare arrangement where couples pay out-of-pocket for infertility services as "unfair, discriminatory and unjust." He emphasized that infertility must be viewed as a public health concern rather than a private financial burden.​



The World Health Organization has defined infertility as a disease and a major disability. As a country, we must see it as such, just as we see other diseases, said Dr. Adageba at the conference, which brought together clinicians, embryologists, nurses, and policymakers under the theme "Reducing the Burden of Infertility in Ghana: Awareness, Preservation, and Infertility Prevention."



FERSOG has submitted a position paper to the National Health Insurance Authority (NHIA) and other stakeholders, advocating for the inclusion of basic infertility services in the National Health Insurance Scheme (NHIS). These services include clinical consultations, semen analysis, hormone profiling, pelvic ultrasound, and intrauterine insemination (IUI). Dr. Adageba noted that the society would continue engaging with the NHIA to establish realistic fees for these services.​



The recognition of infertility as a disease carries significant implications for Ghana's healthcare system. Research indicates that infertility affects approximately 11.8% of women and 15.8% of men in Ghana, with affected couples facing devastating biomedical, psychological, and sociocultural consequences. In Ghanaian society, where children are expected to maintain family lineage and ensure marital stability, the inability to conceive often results in social stigma, discrimination, and psychological distress, particularly for women.​



Currently, Ghana has 22 assisted reproductive technology (ART) centers located in only three of the country's 16 regions, primarily serving middle- and upper-class populations in urban areas. The average cost of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) is approximately 50,000 Ghana Cedis (USD 3,400), far beyond the reach of most Ghanaians, whose national daily minimum wage stands at 19.97 Ghana Cedis (USD 1.4).​



Prof. Dr. Titus Kofi Beyuo, Member of Parliament for Lambussie and member of the Parliamentary Select Committee on Health, announced that the Assisted Reproductive Technologies Bill is at an advanced stage. The Minister of Health is currently working on two key legislative documents: the ART Bill and the Organ Donation and Transplant Medicine Bill. The minister is very committed to passing this bill, Prof. Beyuo assured attendees, encouraging fertility professionals to collaborate more closely with Parliament in their advocacy efforts.​



The conference highlighted that recognizing infertility as a disease would pave the way for regulatory frameworks, standardized care protocols, and financial support through the NHIS. This move would address the current situation where 70.2% of women seeking ART treatment withdraw due to prohibitive costs, and 35.57% discontinue due to partner unavailability.​



FERSOG's advocacy represents a critical step toward achieving reproductive justice in Ghana. By securing disease status for infertility and integrating treatment into the national health insurance scheme, the government could significantly reduce the burden on affected couples and ensure equitable access to fertility care across all socioeconomic classes.

65 views

Share

FertilityIn

Send Enquiry for this Story

Previous News

Births with Infertility Treatments in Korea Rise, Driven by IVF Adoption and Changing Family Planning Trends

Next News

IVI RMA North America Announces Patient Advisory Councils in US and Canada

Related Articles

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.

ART

1 min read

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.

ART

1 min read

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.

ART

1 min read

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.

ART

1 min read

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.

ART

1 min read

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.

ART

1 min read

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address